How much do tigecycline generics cost compared to brand name?

Tigecycline generics cost roughly 40-70% less than Tygacil, the brand-name product. Average wholesale prices show brand-name vials at $250-300 each while generic versions range from $80-150 per vial, though hospital contracts and volume discounts narrow the gap further.

How much do actual acquisition costs vary by hospital size?
Smaller hospitals often pay closer to list price for both versions because they lack the purchasing power of large systems. Large IDNs and GPOs can drive brand acquisition costs down to $150-180 and generic costs to $50-80 per vial.

When do the remaining U.S. patents on tigecycline expire?
The last composition-of-matter patents expired in 2015, but formulation and use patents held by Pfizer extended protection until 2021. Those expirations opened the market to multiple ANDA filers.

Why do some hospitals still buy brand-name Tygacil?
Certain contracts bundle Tygacil with other Pfizer antibiotics at discounted rates that make the brand cheaper than standalone generics. Supply reliability and 340B program pricing also influence the choice.

Can biosimilars enter before all patents clear?
Tigecycline is a small-molecule antibiotic, not a biologic, so biosimilars do not apply. Only conventional generics compete once regulatory exclusivity ends.

What side effects are patients asking about most?
Nausea, vomiting, and increased liver enzymes top patient queries, followed by concerns over higher mortality rates seen in some trials compared with other antibiotics.

[1] DrugPatentWatch.com